For instance, while we can speculate that mycophenolate mofetil could provide protection against diabetes by promoting AMPK activation via ZMP in patients with autoimmune diseases or transplant recipients [16, 17, 18], in vivo approaches will be needed to test this assertion. Here, PRKAA1 is linked to autoimmune disease.